Exscientia (NASDAQ:EXAI) Stock Price Down 5.3% – Should You Sell?

Exscientia plc (NASDAQ:EXAI) traded down 5.3% on Friday . The company traded as low as $5.01 and last traded at $5.03. 147,384 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 640,736 shares. The stock had previously closed at $5.31.

Wall Street Analysts Forecast Growth

EXAI has been the topic of several recent research reports. Barclays reissued an “equal weight” rating and issued a $5.00 price target on shares of Exscientia in a research note on Tuesday, August 13th. TD Cowen reaffirmed a “hold” rating on shares of Exscientia in a research report on Friday, August 9th.

Exscientia Price Performance

The company has a market cap of $595.71 million, a P/E ratio of -3.11 and a beta of 0.83. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.93 and a current ratio of 4.54. The company has a fifty day moving average price of $5.04 and a two-hundred day moving average price of $5.15.

Exscientia (NASDAQ:EXAI) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.05). Exscientia had a negative return on equity of 49.10% and a negative net margin of 882.09%. The company had revenue of $5.60 million for the quarter. On average, sell-side analysts anticipate that Exscientia plc will post -1.25 earnings per share for the current fiscal year.

Institutional Trading of Exscientia

A number of large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its stake in Exscientia by 66.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,576 shares of the company’s stock valued at $47,000 after purchasing an additional 3,821 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Exscientia in the second quarter valued at approximately $54,000. International Assets Investment Management LLC acquired a new position in shares of Exscientia during the 3rd quarter worth approximately $77,000. XTX Topco Ltd bought a new stake in Exscientia in the 3rd quarter valued at $82,000. Finally, Federated Hermes Inc. acquired a new stake in Exscientia during the 2nd quarter valued at $115,000. Institutional investors and hedge funds own 41.58% of the company’s stock.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.